PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9596679-1	1998	In the acute promyelocytic leukemia (APL) cell line NB4, as well as in APL patients" cells, arsenic trioxide (As2O3) leads to incomplete cell maturation, induction of apoptosis, as well as to the degradation of the oncogenic PML/RARalpha fusion protein.	Arsenic Trioxide	92-108	PML nuclear body scaffold	Homo sapiens	225-228	
9596679-1	1998	In the acute promyelocytic leukemia (APL) cell line NB4, as well as in APL patients" cells, arsenic trioxide (As2O3) leads to incomplete cell maturation, induction of apoptosis, as well as to the degradation of the oncogenic PML/RARalpha fusion protein.	Arsenic Trioxide	92-108	retinoic acid receptor alpha	Homo sapiens	229-237	
9596679-1	1998	In the acute promyelocytic leukemia (APL) cell line NB4, as well as in APL patients" cells, arsenic trioxide (As2O3) leads to incomplete cell maturation, induction of apoptosis, as well as to the degradation of the oncogenic PML/RARalpha fusion protein.	Arsenic Trioxide	110-115	PML nuclear body scaffold	Homo sapiens	225-228	
9596679-1	1998	In the acute promyelocytic leukemia (APL) cell line NB4, as well as in APL patients" cells, arsenic trioxide (As2O3) leads to incomplete cell maturation, induction of apoptosis, as well as to the degradation of the oncogenic PML/RARalpha fusion protein.	Arsenic Trioxide	110-115	retinoic acid receptor alpha	Homo sapiens	229-237	
9596679-3	1998	When grown in the presence of As2O3, NB4-AsR cells degrade PML/RARalpha, slightly differentiate, and become more sensitive to serum deprivation-induced apoptosis.	Arsenic Trioxide	30-35	PML nuclear body scaffold	Homo sapiens	59-62	
9596679-3	1998	When grown in the presence of As2O3, NB4-AsR cells degrade PML/RARalpha, slightly differentiate, and become more sensitive to serum deprivation-induced apoptosis.	Arsenic Trioxide	30-35	retinoic acid receptor alpha	Homo sapiens	63-71	
9596679-5	1998	Thus, As2O3- or retinoic acid (RA)-induced PML/RARalpha degradation may be a prerequisite, but is not sufficient for the full differentiative/apoptotic response to these drugs.	Arsenic Trioxide	6-11	PML nuclear body scaffold	Homo sapiens	43-46	
9596679-5	1998	Thus, As2O3- or retinoic acid (RA)-induced PML/RARalpha degradation may be a prerequisite, but is not sufficient for the full differentiative/apoptotic response to these drugs.	Arsenic Trioxide	6-11	retinoic acid receptor alpha	Homo sapiens	47-55	
9596679-5	1998	Thus, As2O3- or retinoic acid (RA)-induced PML/RARalpha degradation may be a prerequisite, but is not sufficient for the full differentiative/apoptotic response to these drugs.	Tretinoin	16-29	PML nuclear body scaffold	Homo sapiens	43-46	
9596679-5	1998	Thus, As2O3- or retinoic acid (RA)-induced PML/RARalpha degradation may be a prerequisite, but is not sufficient for the full differentiative/apoptotic response to these drugs.	Tretinoin	16-29	retinoic acid receptor alpha	Homo sapiens	47-55	
9596679-5	1998	Thus, As2O3- or retinoic acid (RA)-induced PML/RARalpha degradation may be a prerequisite, but is not sufficient for the full differentiative/apoptotic response to these drugs.	Tretinoin	31-33	PML nuclear body scaffold	Homo sapiens	43-46	
9596679-5	1998	Thus, As2O3- or retinoic acid (RA)-induced PML/RARalpha degradation may be a prerequisite, but is not sufficient for the full differentiative/apoptotic response to these drugs.	Tretinoin	31-33	retinoic acid receptor alpha	Homo sapiens	47-55